Breast Cancer
Antibody treatment of breast cancer, such as HER2-targeted monoclonal antibody trastuzumab (Herceptin™), has well-established clinical benefit. As the preferred dimerization partner of human epidermal growth factor receptor 2 (HER2), HER3 acts as an allosteric activator of its partner kinase. HER3, overexpressed in 50%-70% of breast cancer, plays a key role in cancer progression, metastasis development, and drug resistance across all the breast cancer subtypes.